Developing Systemic Therapy for Esophagogastric Cancer

Video
Conference|ASCO Annual Meeting: Gastrointestinal Cancer

Cancer Network spoke with Dr. Karyn Goodman about the importance of developing a systematic therapy regimen for the treatment of esophagogastric cancer.

Cancer Network spoke with Dr. Karyn Goodman about the importance of developing a systematic therapy regimen for the treatment of esophagogastric cancer.

Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Tanio S. Bekaii-Saab, MD, on Potential of Dual Targeting to Transform Treatment of HER2+ CRC
Related Content
High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

Kyle Doherty
June 4th 2025
Article

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Tony Berberabe, MPH
June 2nd 2025
Article

Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.

Evidence Moves OTC Prevention of mCRC Closer to Reality

Evidence Moves OTC Prevention of mCRC Closer to Reality

Andrew T. Chan, MD, MPH
May 27th 2015
Podcast

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

Neoadjuvant PAXG Significantly Improves EFS Over mFOLFIRINOX in Resectable PDAC

Neoadjuvant PAXG Significantly Improves EFS Over mFOLFIRINOX in Resectable PDAC

Jordyn Sava
June 1st 2025
Article

Cisplatin, nab-paclitaxel, gemcitabine, and capecitabine significantly improved EFS vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.

Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer

Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer

Sabrina Serani
June 1st 2025
Article

Five-year follow-up confirms adjuvant nivolumab's sustained disease-free and distant metastasis-free survival benefits in resected esophageal/GEJ cancer post-CRT.